L-Nutra is the leading nutritechnology company, developing innovative Fasting Mimicking & Enhancing Diets (FMEDs) that can be consumed for a predetermined number of consecutive days, with the frequency dependent on the condition and patient. FMEDs nourish the body while keeping it in a fasting mode, which promotes positive long-term effects on biological aging, health and a variety of other factors, such as weight, abdominal fat , and maintaining healthy levels of glucose, cholesterol, blood pressure, and other key health factors.

L-Nutra’s first generation of FMEDs includes ProLon® and Chemolieve®. ProLon® is a 5-day FMED aimed at promoting longevity, managing body weight, and improving health by supporting cellular protection, multi-system regeneration and rejuvenation. ProLon® will be launched in the United States in 2016. Chemolieve® is a 4-day FMED being studied for use with oncology patients to protect the normal cells of the body and decrease side effects of chemotherapy without interfering with its efficacy.

L-Nutra’s first FMED is a 5-day meal program to be consumed every 1 to 6 months based on an authorized healthcare professional’s recommendation. ProLon®, which is designed to promote the body’s natural ability to protect, regenerate and rejuvenate, has been clinically studied to reduce levels of weight, abdominal fat, and maintain healthy levels of blood glucose, C-reactive protein (CRP), and insulin-like growth factor 1 (IGF-1). Unpublished clinical trials indicate that ProLon® may have other positive health benefits. (See www.aboutprolon.com)

L-Nutra’s second FMED is a 4-day meal program currently undergoing clinical testing at 5 different hospitals to evaluate whether it supports the body during chemotherapy and helps with decreasing side effects and recovery. Chemolieve® clinical trials are being conducted at the University of Southern California, Mayo Clinic, Leiden University, and the University of Genoa.
Pipeline of FMEDs

L-Nutra is also developing a pipeline of FMED-based meal programs and will pursue FDA approval for claims related to preventing, delaying or treating chronic diseases, including Cardiovascular and Autoimmune, Metabolic Syndrome, Diabetes, Cardiovascular, Cancer, Alzheimer’s, and Multiple Sclerosis.
A California corporation
Copyright © 2016
All rights reserved.